The intervention strategy Signum Biosciences has developed involves the global modulation of signal transduction networks using a new class of therapeutic agents called Signal Transduction Modulators (STMs). Signaling networks that regulate cellular activities have built-in global control mechanisms to coordinate their many interacting components. Here at Signum, we have identified proprietary molecules that perturb the two most central of these global regulatory mechanisms:
G-protein-mediated signaling
Protein phosphorylation
G-Protein Modulators (GPMs) regulate virtually all G-protein-mediated signaling activities and Phospho-Protein Modulators (PPMs) regulate protein kinase phosphorylation networks. GPMs and PPMs can be used as cosmetics and dietary supplements to correct imbalances that are generally detrimental to health and well being. With appropriate pharmacokinetic and chemical modifications, Signum’s GPMs and PPMs also have tremendous potential for treating the more severe regulatory dysfunctions that underlie a wide range of diseases including atopic dermatitis, rosacea, psoriasis, Alzheimer’s, Parkinson’s and diabetes.
Interested in a job at Signum? Visit our job postings section for a listing of our open positions.